Developmental Research Program

发展研究计划

• 批准号: 10704113
• 负责人: Maurizio Scaltriti
• 金额: $ 6.71万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-13 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10704113
• 关键词: Acceleration; Address; Advocate; Attention; BRCA1 gene; BRCA2 gene; Benchmarking; Biological Markers; Breast Cancer Patient; Breast Cancer Prevention; Breast Cancer Treatment; Budgets; CHEK2 gene; Chromosomal Instability; Chronology; Clinical; Committee Members; Communities; DNA Repair; Data; Defect; Development; Diagnosis; Disease; Doctor of Philosophy; Ensure; Etiology; Fertilization; Fostering; Funding; Future; Generations; Genes; Genetic; Genomic Instability; Genomics; Goals; Grant; High Prevalence; Hospitals; Institution; Investigator-Initiated Research; Knowledge; Leadership; Malignant Neoplasms; Memorial Sloan-Kettering Cancer Center; Mentors; Molecular; Monitor; Mutagenesis; New York; Pathway interactions; Patient Care; Patients; Pattern; Peer Review; Pilot Projects; Platinum; Play; Poly(ADP-ribose) Polymerase Inhibitor; Presbyterian Church; Prevention; Process; Qualifying; Research; Research Personnel; Research Project Grants; Resources; Role; Salts; Selection Criteria; Translational Research; Universities; Voting; anticancer research; arm; base; career; catalyst; community center; genomic signature; high risk; homologous recombination; hormone receptor-positive; hormone therapy; innovation; malignant breast neoplasm; medical schools; optimal treatments; predictive marker; programs; specific biomarkers; success; targeted agent; therapy resistant; translational cancer research; translational goal; translational potential; translational research program; treatment response; triple-negative invasive breast carcinoma; tumor

Project Abstract/ Summary (DRP) Breast cancers frequently harbor specific patterns of homologous recombination (HR) DNA repair defects (HRD) and/or specific patterns of genetic instability, namely chromosomal instability (CIN) and APOBEC mutagenesis. These alterations are present in a substantial proportion of breast cancers and they are enriched in metastatic disease. Biomarkers to identify these patients reliably and to define the optimal treatments for these patients are sorely needed. The Developmental Research Program (DRP) will play an important role in fostering translational research endeavors focusing on breast cancer, in particular research addressing specific patterns of DNA repair defects and/or genetic instability and their molecular basis. We will use DRP funding supplemented by a strong commitment of institutional funds to support innovative projects by new and established investigators, which are critical to the generation of new ideas in the diagnosis and treatment of this large subset of breast cancers. Our goal is to establish mechanisms for rapid funding of important new directions to accelerate progress towards the translational research goals of our SPORE. We identified a credible portfolio of promising developmental research projects, which will be competing for support once the program is established. We will request pilot project proposals with translational potential from clinical and basic investigators within the larger MSKCC community, including Rockefeller University, New York-Presbyterian Hospital and Weill Cornell Medical College of Cornell University. We will then select the most promising new projects for support after rigorous peer review by the Leadership Committee, the Internal Advisory Board and the Patient Advocates. The opinion of external reviewers will be solicited as needed. Pilot projects will be funded for 1 year, but investigators may apply for additional funding through this same competitive process the next year. Every year the Advisory and Leadership Committee members will meet to review each research project, core, career enhancement project and developmental pilot project. Committee members will be asked to assess whether any developmental project has progressed sufficiently and shown enough translational potential, so as to eclipse one of the full SPORE Research Projects. The committee members will then vote and decide whether any developmental project should be advanced to full project status. If so, the budgets will be appropriately adjusted and sent for approval with the TRP of the NCI.

项目摘要/摘要（DRP） 乳腺癌经常具有同源重组（HR）DNA修复缺陷（HRD）的特定模式 和/或遗传不稳定性的特定模式，即染色体不稳定性（CIN）和APOBEC诱变。 这些改变存在于很大一部分的乳腺癌中，并且富含转移性 疾病。可靠地识别这些患者并定义这些患者的最佳治疗的生物标志物是 非常需要。发展研究计划（DRP）将在培养翻译中发挥重要作用 研究重点是乳腺癌的研究，特别是针对DNA修复的特定模式的研究 缺陷和/或遗传不稳定性及其分子基础。我们将使用强大的DRP资金 机构资金的承诺，以支持新的和成熟的调查人员的创新项目，这是 对于诊断和治疗这一大部分乳腺癌的诊断和治疗至关重要的。我们的 目标是建立快速资助重要新方向的机制，以加速进步 我们孢子的翻译研究目标。我们确定了有希望发展的可信作品集 研究项目，一旦建立该计划，该项目将争夺支持。我们将要求飞行员 较大MSKCC中临床和基本研究人员的转化潜力的项目建议 社区，包括洛克菲勒大学，纽约长老会医院和威尔·康奈尔医学院 康奈尔大学。然后，我们将在严格的同行评审后选择最有希望的新项目以支持 由领导委员会，内部顾问委员会和患者倡导者。外部意见 审稿人将根据需要征求征求意见。试点项目将获得1年的资金，但调查人员可以申请 明年通过相同的竞争过程进行额外资金。每年咨询和领导 委员会成员将开会以审查每个研究项目，核心，职业增强项目和 发展试点项目。将要求委员会成员评估是否有任何发展项目 进步足够充分并显示出足够的翻译潜力，以蚀是全孢子之一 研究项目。然后，委员会成员将投票并决定是否应有任何发展项目 提高到完整的项目状态。如果是这样，预算将得到适当调整并发送批准 NCI的TRP。